U.S. FDA clears Israeli startup Sight Diagnostics' finger prick blood test -- MEDICA - World Forum for Medicine

04/12/2019

S.D Sight Diagnostics Ltd.

U.S. FDA clears Israeli startup Sight Diagnostics' finger prick blood test

The regulator’s nod means that laboratories that run relatively lesser tests on a day to day basis may also be able to conduct the complete blood count (CBC) test with just two drops of blood.

“This could be a big change because at the moment a traditional analyzer can be placed in laboratories that run thousands of tests every week,” said Sarah Levy, chief technical officer at Sight Diagnostics.

CBC is a blood test that gives a snapshot of one’s overall health and can also used to detect leukemia. The FDA clearance could bring down costs at laboratories with lower volumes, as traditional CBC tests which use a technology known as flow cytometry, normally require dedicated personnel to maintain the device, adding to costs.

Exhibitor Data Sheet